Encouraging results from preclinical and clinical studies support the development of bNAbs
for prevention and a number of antibodies with exceptional breadth and potency are …

Summary bNAbs may offer advantages over traditional ART for both the prevention and
treatment of HIV-1 infection. In addition, bNAbs may target the latent viral reservoir. bNAb …

Early clinical studies support additional evaluation of bNAbs. Antibodies may offer
advantages over standard ART for HIV-1 prevention and therapy, and as components of …

Despite immense progress in our ability to prevent and treat HIV-1 infection, HIV-1 remains
an incurable disease and a highly efficacious HIV-1 vaccine is not yet available. Additional …

Introduction The last 12 years have seen remarkable progress in the isolation and
characterization of at least five different epitope classes of HIV‐specific broadly neutralizing …

Broadly neutralizing antibodies for treatment and prevention... : Current Opinion in HIV and
AIDS Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection : Current …

Antibodies that naturally develop in some individuals infected with human immunodeficiency
virus 1 (HIV-1) and are capable of broadly neutralizing diverse strains of HIV-1 are useful for …

Given the absence of an effective vaccine for protection against HIV-1 infection, passive
immunization strategies that utilize potent broadly neutralizing antibodies (bnAbs) to block …

Despite the discovery that the human immunodeficiency virus 1 (HIV-1) is the pathogen of
acquired immunodeficiency syndrome (AIDS) in 1983, there is still no effective anti-HIV-1 …

In the last decade, over a dozen potent broadly neutralizing antibodies (bnAbs) to several
HIV envelope protein epitopes have been identified, and their in vitro neutralization profiles …